There is a clear need for a safe, reliable and consistent method of delivering compounds across the BBB, and assessing their neuro-pharmacokinetics in brain ECF.
CerenseSM provides the vital key by overcoming the twin obstacles that block the creation of successful CNS therapeutics. It can be used to:
- substantially improve BBB penetration of potential CNS drugs whose utility is constrained by poor BBB penetration.
- reduce the likelihood of safety issues associated with off-target pharmacological interactions outside the CNS.
- extend and enhance the patent life of existing CNS drugs.
